L’essor de l’intelligence artificielle, du Big Data, de la blockchain et de la télémédecine ouvre de nouvelles perspectives pour une médecine plus personnalisée, efficace et accessible. La digitalisation n’est plus une option mais une nécessité stratégique pour améliorer l’efficacité des soins.

GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.

Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.

Créée en 2022, DrugOptimal développe une application logicielle à destination des établissements de santé, et en particulier des infirmiers et les pharmaciens, pour mieux prévenir les risques d'incompatibilités physicochimiques médicamenteuses.

Microplastics are everywhere—in our water, food, and even the air we breathe. A new scientific review highlights a growing concern: microplastics and nanoplastics are accumulating in human brain tissue. Researchers are now investigating what this could mean for brain health and how we can reduce our exposure.

For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.

For decades, EMS has relied on blood component therapy, which was favored for its longer shelf life, efficiency, and lower risk of transfusion reactions. However, emerging data suggests that whole blood transfusion in the field could significantly improve survival rates, particularly in rural and remote areas where longer transport times pose additional risks.

Having some belly fat may be beneficial for brain health in younger individuals due to its role in maintaining healthy BDNF. Aging disrupts this benefit because of decreased production of a key protein, CX3CL1. This leads to lower BDNF levels and potentially contributes to cognitive decline. Excessive fat accumulation, particularly in obesity, is associated with overexpression of 11β-HSD1, which is linked to negative metabolic effects.

Each polymer reacts differently to ionizing radiation. Thus, it is important to verify that the maximum administered dose will not have a detrimental effect on the product’s function or the patient’s safety over the product’s intended shelf life.

Considering that dose rate had no impact on sterilization efficacy,
the data suggests that an easier transition can be obtained within
different ionizing radiation technologies without extensive work related to the sterilization effects as a function of the dose rate. That is, the results reported herein suggest that transfer of minimum doses required for inactivation is possible between irradiators of the same and/or different irradiation source without impacting the sterility assurance level (SAL), in accordance with ISO11137-2:2013.

Over about 3.5 years, Al-Aly and his colleagues tracked more than 200,000 people with diabetes on GLP-1 drugs and about 1.7 million people with diabetes using other blood-sugar-lowering medications. They tracked the effects of GLP-1 drugs on 175 health conditions. Compared with other diabetes medications, GLP-1 drugs were linked to a lower risk of dozens of conditions, including heart disease, stroke and kidney disease. They also lowered the risk of psychotic disorders by 18%, Alzheimer’s disease by 12%, and addiction disorders by an average of 13%.

Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.

By moving beyond adherence and drug interactions to a holistic, outcomes-driven approach, health systems and providers can redefine how medication is used — not as a rigid protocol but as a dynamic, patient-centered tool for achieving better health.

Robert F. Kennedy Jr.’s rise to become secretary of the Department of Health and Human Services has some concerned that anti-vaccine policies are coming. If the nation’s top public health agency pulls support of vaccination, other healthcare stakeholders will need to step up to fill the vaccine messaging void.

The integration of advanced materials into drug delivery systems has become the new normal in pharmaceutical science to address the complexity of modern medicine. These innovations have used technologies such as nanocarriers, hydrogels, and bioresponsive polymers to enable precision, efficiency, and superior therapeutic outcomes. Advanced materials have revolutionized drug delivery by improving upon conventional systems, and their application in various fields, including oncology, chronic disease management, and vaccine delivery, has been remarkable.

Last month, the Japanese pharma deprioritized the development of mezagitamab, also known as TAK-079, in myasthenia gravis and systemic lupus erythematosus as part of a wider pipeline shake-up. But the team said at the time that it was still planning to continue to clinically evaluate the antibody in ITP.

Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.

New research found that most healthcare CFOs anticipate minimal financial gains this year due to high labor costs and insufficient payer rates. While providers are leveraging more data to improve financial planning, persistent challenges like wage pressures, recruiting difficulties and payers' increasing use of technology to deny claims continue to strain margins.

AbbVie is licensing rights to a drug from Gubra that has encouraging early clinical data in obesity. The once-weekly injectable peptide is a dual agonist of the amylin and calcitonin receptors, both of which play key roles in metabolism.

In the study, the DN gel rapidly reprogrammed differentiated cancer cells into cancer stem cells in just 24 hours in six different human cancer cell lines — brain cancer, uterine cancer, lung cancer, colon cancer, bladder cancer, and sarcoma. After cancer cells were placed on the DN gel, they started to form spherical structures and produce specific molecules known to be markers of cancer stem cells such as SOX2 and Oct3/4, aka Yamanaka factors, named after the Nobel Prize laureate, suggesting they had been reprogrammed.

The U.S. Food and Drug Administration requires testing be performed on new medical devices requiring sterility and on legacy medical devices that a manufacturer desires to switch to another sterilization method to ensure safety (functionality, biocompatibility, and ability to sterilize). ISO 11137-1 guidance provides expectation of being able to transfer maximum acceptable dose from a low dose rate gamma sterilization process to a higher dose rate e-beam or x-ray process.

Looking for alternatives to gamma irradiation? Many gamma sterilized products are compatible with electron beam. With the recent publication of AAMI TIR 104, the process for transferring products from gamma to electron beam is now simple and well defined.

Ces dispositifs miniaturisés peuvent accomplir des missions spécifiques telles que des biopsies, la délivrance de molécules ou encore l’implantation d’électrodes. « Ce financement représente une étape cruciale pour doter les neurochirurgiens des outils nécessaires pour transformer les traitements et les résultats pour les patients », ajoute-t-il.